J P Morgan Chase & Co upgraded shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from a neutral rating to an overweight rating in a research note issued to investors on Thursday morning, MarketBeat reports.

Other analysts have also recently issued research reports about the company. BidaskClub cut Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Wednesday, August 16th. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a buy rating in a research report on Wednesday, September 20th. Ladenburg Thalmann Financial Services set a $90.00 target price on Alnylam Pharmaceuticals and gave the stock a buy rating in a research report on Monday, July 17th. Chardan Capital reiterated a buy rating and set a $124.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, September 25th. Finally, Stifel Nicolaus reiterated a buy rating and set a $56.00 target price (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $114.57.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $139.98 on Thursday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter last year, the firm posted ($1.21) EPS. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. sell-side analysts anticipate that Alnylam Pharmaceuticals will post -5.25 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-upgraded-at-j-p-morgan-chase-co/1699174.html.

In other news, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total value of $2,600,000.00. Following the sale, the director now directly owns 20,000 shares in the company, valued at approximately $2,600,000. The disclosure for this sale can be found here. Insiders sold a total of 215,797 shares of company stock worth $25,035,072 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the company. QS Investors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 900 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 167 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $215,000. CIBC Asset Management Inc purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $221,000. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $229,000. 92.73% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.